Aug 18, 2009 | Posted by: roboblogger
LEXINGTON, Mass. & SAN FRANCISCO-- --Aug 12, 2009 - Antigenics Inc. today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage in combination with the standard of care - radiation therapy plus Temodar - for newly diagnosed glioma ...
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
|
|
Apr '09 | Researcher | 1 |
|
|
Mar '08 | ihatesnow | 1 |